DNA X, Inc.
SONM
$3.94
-$0.54-12.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.31% | 4.17% | -16.41% | -31.16% | -37.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.31% | 4.17% | -16.41% | -31.16% | -37.74% |
| Cost of Revenue | -9.11% | -26.00% | -47.24% | -53.54% | -50.98% |
| Gross Profit | 59.99% | -8.24% | 0.42% | -31.64% | -64.37% |
| SG&A Expenses | 74.39% | -78.47% | -75.29% | -78.07% | -81.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.39% | -96.49% | -100.45% | -100.33% | -96.67% |
| Operating Income | -74.39% | 87.24% | 99.71% | 109.33% | -704.29% |
| Income Before Tax | -175.93% | 80.51% | 97.31% | 117.20% | -1,115.14% |
| Income Tax Expenses | 29.39% | -2.96% | 10.54% | -25.91% | -25.40% |
| Earnings from Continuing Operations | -175.93% | 80.44% | 96.35% | 114.92% | -3,103.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.61% | -149.38% | -200.96% | -839.62% | -37,286.67% |
| EBIT | -74.39% | 87.24% | 99.71% | 109.33% | -704.29% |
| EBITDA | -342.01% | 122.54% | 152.95% | 7,310.91% | -82.78% |
| EPS Basic | 78.97% | -91.04% | -156.51% | -790.93% | -88,205.43% |
| Normalized Basic EPS | 26.94% | 137.07% | 137.34% | 118.33% | -865.53% |
| EPS Diluted | 78.91% | -91.12% | -156.28% | -773.76% | -32,047.25% |
| Normalized Diluted EPS | 26.86% | 137.05% | 137.25% | 117.94% | -992.86% |
| Average Basic Shares Outstanding | 146.57% | 105.56% | 39.66% | 15.61% | 9.74% |
| Average Diluted Shares Outstanding | 146.73% | 105.72% | 38.94% | 13.49% | 7.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |